News
Sagimet Biosciences Announces Completion Of Phase 1 Hepatic Impairment Study With FASN Inhibitor Denifanstat
27 Mar 24
Biotech, News, General
Goldman Sachs Maintains Buy on Sagimet Biosciences, Lowers Price Target to $27
26 Mar 24
News, Price Target, Analyst Ratings
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
25 Mar 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Monday's Intraday Session
25 Mar 24
Movers
Leerink Partners Initiates Coverage On Sagimet Biosciences with Outperform Rating, Announces Price Target of $26
25 Mar 24
News, Price Target, Initiation, Analyst Ratings
12 Health Care Stocks Moving In Friday's After-Market Session
16 Feb 24
Movers
JMP Securities Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $46
7 Feb 24
News, Price Target, Analyst Ratings
Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
6 Feb 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Tuesday's Intraday Session
6 Feb 24
Movers
Press releases
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
27 Mar 24
Health Care, Press Releases
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
25 Mar 24
News, Management, Press Releases
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
25 Mar 24
Earnings, Press Releases